Рак простаты

Apalutamide/ADT Improves EFS vs Surgery Alone in High-Risk Prostate Cancer

DASL-HiCaP at ESMO 2026: Darolutamide Plus ADT and Radiotherapy in Very High-Risk Prostate Cancer

DASL-HiCaP at ESMO 2026: Darolutamide Plus ADT and Radiotherapy in Very High-Risk Prostate Cancer Oncodaily

ESMO26: Halda buy delivers a win for J&J in prostate cancer

ESMO26: Halda buy delivers a win for J&J in prostate cancer pharmaphorum

J&J prostate cancer drug shows promising tumor responses in early trial

J&J prostate cancer drug shows promising tumor responses in early trial Investing.com

Diagnostic test could help doctors refine prostate cancer treatment

Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer does not behave the same way in every patient, and doctors have long faced a difficult balancing act between identifying patients who will benefit from more intensive treatment and those who may…

Real-world results confirm benefit of PSMA therapy for prostate cancer

Real-world results confirm benefit of PSMA therapy for prostate cancer EurekAlert!

Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress

Real-world results confirm benefit of antigen therapy for prostate cancer

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, consistent with outcomes from the VISION trial. An analysis of outcomes from a French early-access program, the…

Genomic Test Predicts Which Prostate Cancer Patients Benefit From Abiraterone Therapy

Genomic Test Predicts Which Prostate Cancer Patients Benefit From Abiraterone Therapy Clinical Lab Products

Decipher tissue-based molecular test helps personalize high-risk prostate cancer treatment - News-Medical

Decipher tissue-based molecular test helps personalize high-risk prostate cancer treatment News-Medical

CAPItello-281 at ESMO 2026: Capivasertib Plus Abiraterone Shows Promising Survival Results in PTEN-Deficient Prostate Cancer

CAPItello-281 at ESMO 2026: Capivasertib Plus Abiraterone Shows Promising Survival Results in PTEN-Deficient Prostate Cancer Oncodaily

KEYNOTE-365 Cohort I at ESMO 2026: Pembrolizumab Plus Chemotherapy in Neuroendocrine Prostate Cancer

KEYNOTE-365 Cohort I at ESMO 2026: Pembrolizumab Plus Chemotherapy in Neuroendocrine Prostate Cancer Oncodaily

Prostate Cancer Drug Shows Promise in New Clinical Trial | Newswise

Prostate Cancer Drug Shows Promise in New Clinical Trial | Newswise Newswise

Prostate Cancer Drug Shows Promise in New Clinical Trial

Prostate Cancer Drug Shows Promise in New Clinical Trial Yale School of Medicine

Clinical Trial Information on New T-Cell Treatment for Advanced Prostate Cancer

Clinical Trial Information on New T-Cell Treatment for Advanced Prostate Cancer Cancer Health